CMV reactivation after allogeneic stem cell transplant in children in Italy.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective observational chart review of pediatric patients who received allogeneic HSCT at about five major Italian centers, capturing consecutive transplants from January 2018 to June 2020 with up to 12 months of follow-up. Investigators will extract data from inpatient and outpatient electronic or paper medical records to describe patient characteristics, CMV risk factors, treatment patterns, clinical outcomes, and healthcare resource use. Patients who received letermovir at any time are excluded to avoid treatment-related bias. The goal is to quantify the clinical and economic burden of CMV reactivation to inform clinicians, guideline committees, and payers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients from birth to less than 18 years of age (at the moment of the allogeneic HSCT);
* Patients who received allogeneic HSCT between January 2018 and June 2020;
* Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF), if applicable.

Exclusion Criteria:

* Letermovir use at any time

Where it's running

• IRCCS Istituto Giannina Gaslini, Trapianto di Cellule Staminali Emopoietiche, Dipartimento di Onco-Ematologia Pediatrica
  Genova, Italy Recruiting
• Ospedale San Gerardo, Clinica Pediatrica
  Monza, Italy Recruiting
• IRCCS Ospedale Pediatrico Bambino Gesù, Dipartimento di Pediatria Ematologia e Oncologia
  Roma, Italy Recruiting
• Ospedale Infantile Regina Margherita, Dipartimento Patologia e Cura del Bambino
  Torino, Italy Recruiting
• Azienda Ospedale-Università di Padova, Clinica di Oncoematologia Pediatrica
  Padova, Italy Not yet recruiting

Study contacts

• Study coordinator: Antonia Maffucci
• Email: info.studiclinici@opisresearch.com
• Phone: +39 03626331

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining letermovir and valganciclovir to treat cytomegalovirus infections in kidney transplant patients

  This study is testing if a combination of two medications, letermovir and valganciclovir, can better treat cytomegalovirus infections in kidney transplant patients compared to just using valganciclovir alone.

  Recruiting at 5 sites Phase 3 Assistance Publique - Hôpitaux de Paris · Paris and 4 other locations · NCT06334497

• Evaluating a software tool for diagnosing CMV infection in pregnant women

  This study is testing a new software tool to help doctors quickly and accurately diagnose CMV infections in pregnant women to ensure timely treatment for the health of the baby.

  Recruiting at 3 sites Assistance Publique - Hôpitaux de Paris · Limoges and 2 other locations · NCT06694428

• G‑CSF plus IL‑11 for faster blood recovery after autologous stem cell transplant

  This phase 2 trial will test whether adding IL‑11 to G‑CSF improves mobilization and speeds platelet and red blood cell recovery in adults having autologous stem cell transplant for multiple myeloma or lymphoma.

  Recruiting at 7 sites Phase 2 Fudan University · Fuzhou, Fujian and 6 other locations · NCT07362810

• Hyperbaric oxygen effects on circulating blood-forming stem cells

  This trial will try hyperbaric oxygen therapy to see if it increases circulating hematopoietic stem cells in adults aged 20–80 who are starting HBOT for another medical reason.

  Recruiting Assaf-Harofeh Medical Center · Zrifin · NCT06748586

• Characterization of CD180 Protein Expression in Myeloid Blood C cancers

  This study tests how CD180 is presented on myeloid cancer cells and normal stem cells using existing patient samples from AML cases to see if it could help with diagnosis or monitoring.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07895901

• Population PK-guided ATG Dosing in Haploidentical Stem Cell Transplant

  This trial tests a population PK-guided ATG dosing strategy in people undergoing haploidentical hematopoietic stem cell transplantation to see if it improves outcomes.

  Recruiting Phase 3 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07862127

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.